Optimal Pharmacologic Treatment Strategies in Obesity and Type 2 Diabetes

Journal of Clinical Medicine

Gayotri Goswami²  Nataliya Shinkazh¹ 

[1] Touro College of Pharmacy, New York, NY 10027, USA; E-Mail:;North Bronx Healthcare Network, 3424 Kossuth Avenue, Bronx, NY 10467, USA; E-Mail:

关键词: obesity;    type 2 diabetes;    obesity;    obese diabetics;    weight neutral diabetes medications;    anti-obesity drugs;    weight loss in diabetes;   

DOI  :  10.3390/jcm3020595

来源: mdpi

【 摘 要 】

The prevalence of obesity has increased to pandemic levels worldwide and is related to increased risk of morbidity and mortality. Metabolic comorbidities are commonly associated with obesity and include metabolic syndrome, pre-diabetes, and type 2 diabetes. Even if the prevalence of obesity remains stable until 2030, the anticipated numbers of people with diabetes will more than double as a consequence of population aging and urbanization. Weight reduction is integral in the prevention of diabetes among obese adults with pre-diabetes. Lifestyle intervention and weight reduction are also key in the management of type 2 diabetes. Weight loss is challenging for most obese patients, but for those with diabetes, it can pose an even greater challenge due to the weight gain associated with many treatment regimens. This article will review optimal treatment strategies for patients with comorbid obesity and type 2 diabetes. The role of anti-obesity agents in diabetes will also be reviewed. This literature review will provide readers with current strategies for the pharmacologic treatment of obesity and diabetes with a focus on the weight outcomes related to diabetes treatments.

【 授权许可】

CC BY   
© 2014 by the authors; licensee MDPI, Basel, Switzerland.